• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GMAB

    Genmab A/S

    Subscribe to $GMAB
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: genmab.com

    Recent Analyst Ratings for Genmab A/S

    DatePrice TargetRatingAnalyst
    9/23/2025$43.00Neutral → Buy
    Guggenheim
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    10/8/2024Buy
    Redburn Atlantic
    9/4/2024$31.00Equal-Weight
    Morgan Stanley
    8/20/2024Overweight → Neutral
    JP Morgan
    7/15/2024Sector Perform → Outperform
    RBC Capital Mkts
    2/23/2024$46.00 → $48.00Market Perform → Outperform
    BMO Capital Markets
    1/22/2024Neutral → Sell
    Citigroup
    See more ratings

    Genmab A/S SEC Filings

    View All

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    9/30/25 11:27:34 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    9/29/25 6:08:32 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    9/25/25 7:16:33 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    9/23/25 10:56:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    9/10/25 12:01:55 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    9/9/25 3:02:33 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    8/13/25 10:35:56 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    8/12/25 3:11:58 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    8/7/25 11:38:58 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    8/7/25 10:33:14 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab A/S Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Major Shareholder Announcement

    Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of September 19, 2025, Orbis Investment Management Limited through shares and ADRs, representing shares, controlled the voting rights to 3,230,732 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S.   The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company with

    9/23/25 9:18:27 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient setting Adverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients Data also demonstrated 64.3% overall response rate with a complete response rate of 47.6% in patients treated with epcoritamab following one prior line of systemic DLBCL therapy Genmab A/S (NASDAQ:GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT0

    9/3/25 8:30:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

    Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy Regulatory decision supported by data from the Phase 1/2 RAINFOL™-01 trial showing encouraging responses in heavily pretreated EC patientsi Rina-S continues to be evaluated as a single-agent in patients with advanced EC in the Phase 1/2 RAINFOL™-01 trial and will be further evaluated in a planned Phase 3 trial Genmab A/S (NASDAQ:GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough The

    8/26/25 8:00:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million. The increase corresponds to approximately 0.01% of the company's share capital. The new shares are ordinary shares without any special rights and are freely tra

    8/12/25 2:36:02 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

    Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value <0.0001) versus R2 alone in patients with relapsed/refractory (R/R) Follicular Lymphoma (FL) Results from EPCORE FL-1 form the basis of global regulatory submissions U.S. FDA has accepted for priority review new supplemental Biologics License Application (sBLA) for epcoritamab plus R2, with action date of November 30, 2025 If approved, epcoritamab plus R2 would be the first bispecific antibody combination regimen available as a second-line treatment option for patients wi

    8/7/25 10:31:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

    Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value <0.0001) versus R2 alone in patients with relapsed/refractory (R/R) Follicular Lymphoma (FL) Results from EPCORE FL-1 form the basis of global regulatory submissionsU.S. FDA has accepted for priority review new supplemental Biologics License Application (sBLA) for epcoritamab plus R2, with action date of November 30, 2025If approved, epcoritamab plus R2 would be the first bispecific antibody combination regimen available a

    8/7/25 10:30:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

    Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,539 million in the second quarter of 2025. Net trade sales were USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world. Genmab receives royalties on the w

    7/16/25 6:29:31 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab A/S Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

    Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

    2/22/21 8:00:51 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab A/S Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/8/24 10:03:08 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/2/24 2:18:06 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genmab A/S

    SC 13G - GENMAB A/S (0001434265) (Subject)

    2/6/23 2:36:15 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab A/S Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Genmab upgraded by Guggenheim with a new price target

    Guggenheim upgraded Genmab from Neutral to Buy and set a new price target of $43.00

    9/23/25 7:47:11 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab downgraded by Bernstein

    Bernstein downgraded Genmab from Mkt Perform to Underperform

    4/1/25 9:01:35 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab upgraded by William Blair

    William Blair upgraded Genmab from Mkt Perform to Outperform

    3/11/25 7:35:51 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Genmab from Market Perform to Outperform and set a new price target of $27.00

    2/13/25 7:09:15 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Redburn Atlantic initiated coverage on Genmab

    Redburn Atlantic initiated coverage of Genmab with a rating of Buy

    10/8/24 7:27:12 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Genmab with a new price target

    Morgan Stanley resumed coverage of Genmab with a rating of Equal-Weight and set a new price target of $31.00

    9/4/24 7:41:59 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab downgraded by JP Morgan

    JP Morgan downgraded Genmab from Overweight to Neutral

    8/20/24 8:47:44 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab upgraded by RBC Capital Mkts

    RBC Capital Mkts upgraded Genmab from Sector Perform to Outperform

    7/15/24 7:45:38 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Genmab from Market Perform to Outperform and set a new price target of $48.00 from $46.00 previously

    2/23/24 7:03:20 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab downgraded by Citigroup

    Citigroup downgraded Genmab from Neutral to Sell

    1/22/24 10:44:49 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab A/S Financials

    Live finance-specific insights

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million. The increase corresponds to approximately 0.01% of the company's share capital. The new shares are ordinary shares without any special rights and are freely tra

    8/12/25 2:36:02 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. Proceeds to the company are approximately DKK 33.3 million. The increase corresponds to approximately 0.05% of the company's share capital. The new shares are ord

    6/17/25 1:34:35 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

    Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38 Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a

    3/10/25 10:21:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

    Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT COPENHAGEN, Denmark; March 10, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising

    3/10/25 10:13:07 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Publishes 2024 Annual Report

    Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email

    2/12/25 11:01:37 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

    Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumors Genmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab

    4/3/24 1:35:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

    Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian cancer and other solid tumorsGenmab to host conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark and SEATTLE, Washington; April 3, 2024 – Genmab A/S (NASDAQ:GMAB) and ProfoundBio, Inc. announced today that the companies have

    4/3/24 1:34:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Publishes 2023 Annual Report

    Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for 2024. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investors. Conference CallGenmab will hold a conference call in English to discuss the full year results for 2023 today, February 14, 2024 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive

    2/14/24 11:02:14 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care